Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Por um escritor misterioso
Descrição
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC
PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Frontiers Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Frontiers Therapeutic strategies for gastric cancer targeting immune cells: Future directions
PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Full article: Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
Wnt/β-catenin signaling in cancers and targeted therapies
Vaccines, Free Full-Text
Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
de
por adulto (o preço varia de acordo com o tamanho do grupo)
